Search

Your search keyword '"Min, Chang-Ki"' showing total 10 results
Start Over Author "Min, Chang-Ki" Journal therapeutic advances in hematology
10 results on '"Min, Chang-Ki"'

1. Superior survival outcome of blinatumomab compared with conventional chemotherapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia: a propensity score–matched cohort analysis

Author

Yoon, Jae-Ho, primary, Kwag, Daehun, additional, Lee, Jong-Hyuk, additional, Min, Gi June, additional, Park, Sung-Soo, additional, Park, Silvia, additional, Lee, Sung-Eun, additional, Cho, Byung-Sik, additional, Eom, Ki-Seong, additional, Kim, Yoo-Jin, additional, Kim, Hee-Je, additional, Min, Chang-Ki, additional, Cho, Seok-Goo, additional, Wook Lee, Jong, additional, and Lee, Seok, additional

Published
2023
Full Text
View/download PDF

2. A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML)

Author

Park, Silvia, primary, Kwag, Daehun, additional, Kim, Tong Yoon, additional, Lee, Jong Hyuk, additional, Lee, Joon yeop, additional, Min, Gi June, additional, Park, Sung Soo, additional, Yahng, Seung-Ah, additional, Jeon, Young-Woo, additional, Shin, Seung-Hwan, additional, Yoon, Jae-Ho, additional, Lee, Sung-Eun, additional, Cho, Byung Sik, additional, Eom, Ki-Seong, additional, Kim, Yoo-Jin, additional, Lee, Seok, additional, Min, Chang-Ki, additional, Cho, Seok-Goo, additional, Lee, Jong Wook, additional, and Kim, Hee-Je, additional

Published
2022
Full Text
View/download PDF

3. Durable outcomes of double cord blood transplantation in adults with acute lymphoblastic leukemia: high-risk features for early and long-term mortality

Author

Yoon, Jae-Ho, primary, Min, Gi June, additional, Park, Sung-Soo, additional, Park, Silvia, additional, Lee, Sung-Eun, additional, Cho, Byung-Sik, additional, Eom, Ki-Seong, additional, Kim, Yoo-Jin, additional, Kim, Hee-Je, additional, Min, Chang-Ki, additional, Cho, Seok-Goo, additional, Lee, Jong Wook, additional, and Lee, Seok, additional

Published
2022
Full Text
View/download PDF

4. Natural-killer cell cytotoxicity as a diagnostic and prognostic marker for adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective phase II observational study

Author

Oh, Eun-Jee, primary, Yoon, Jae-Ho, additional, Park, Ki Hyun, additional, Bae, Hyun Joo, additional, Yun, So Jeong, additional, Min, Gi June, additional, Park, Sung-Soo, additional, Park, Silvia, additional, Lee, Sung-Eun, additional, Cho, Byung-Sik, additional, Eom, Ki-Seong, additional, Kim, Yoo-Jin, additional, Lee, Seok, additional, Kim, Hee-Je, additional, Min, Chang-Ki, additional, Cho, Seok-Goo, additional, Han, Kyungja, additional, and Lee, Jong Wook, additional

Published
2021
Full Text
View/download PDF

5. Hepatic venoocclusive disease/sinusoidal obstruction syndrome with normal portal vein flow mimicking aggravated chronic hepatic GVHD following inotuzumab ozogamicin salvage therapy: a case report of pathologic-radiologic discrepancy

Author

Lee, Joonyeop, primary, Yoon, Jae-Ho, additional, Kwag, Daehun, additional, Lee, Jong-Hyuk, additional, Kim, Tong Yoon, additional, Min, Gi June, additional, Park, Sung-Soo, additional, Park, Silvia, additional, Lee, Sung-Eun, additional, Cho, Byung-Sik, additional, Eom, Ki-Seong, additional, Kim, Yoo-Jin, additional, Kim, Hee-Je, additional, Min, Chang-Ki, additional, Cho, Seok-Goo, additional, Wook Lee, Jong, additional, Hak Lee, Sung, additional, and Lee, Seok, additional

Published
2021
Full Text
View/download PDF

6. Differential effects of donor lymphocyte infusion upon treatment response and GVHD according to relapse level and donor sources in patients with myelodysplastic syndrome

Author

Park, Silvia, primary, Kim, Tong Yoon, additional, Lee, Jong Hyuk, additional, Lee, Joon yeop, additional, Min, Gi June, additional, Park, Sung Soo, additional, Yahng, Seung-Ah, additional, Shin, Seung-Hwan, additional, Yoon, Jae-Ho, additional, Lee, Sung-Eun, additional, Cho, Byung Sik, additional, Eom, Ki-Seong, additional, Lee, Seok, additional, Kim, Hee-Je, additional, Min, Chang-Ki, additional, Lee, Jong Wook, additional, and Kim, Yoo-Jin, additional

Published
2021
Full Text
View/download PDF

7. Experiences of allogeneic hematopoietic cell transplantation following non-myeloablative conditioning regimen in severely comorbid patients with myelofibrosis: case series with a patient presenting with extensive extramedullary hematopoiesis

Author

Yoon, Jae-Ho, primary, Park, Sung-Soo, additional, Min, Gi June, additional, Park, Silvia, additional, Lee, Sung-Eun, additional, Cho, Byung-Sik, additional, Kim, Yoo-Jin, additional, Lee, Seok, additional, Kim, Hee-Je, additional, Min, Chang-Ki, additional, Cho, Seok-Goo, additional, Lee, Jong Wook, additional, and Eom, Ki-Seong, additional

Published
2020
Full Text
View/download PDF

8. HLA-mismatched donor and high ferritin level showed poor clinical outcomes after allogeneic hematopoietic cell transplantation in patients with advanced myelofibrosis

Author

Yoon, Jae-Ho, primary, Min, Gi June, additional, Park, Sung-Soo, additional, Park, Silvia, additional, Lee, Sung-Eun, additional, Cho, Byung-Sik, additional, Kim, Yoo-Jin, additional, Lee, Seok, additional, Kim, Hee-Je, additional, Min, Chang-Ki, additional, Cho, Seok-Goo, additional, Lee, Jong Wook, additional, and Eom, Ki-Seong, additional

Published
2020
Full Text
View/download PDF

9. A retrospective comparison of salvage intensive chemotherapy versusvenetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML)

Author

Park, Silvia, Kwag, Daehun, Kim, Tong Yoon, Lee, Jong Hyuk, Lee, Joon yeop, Min, Gi June, Park, Sung Soo, Yahng, Seung-Ah, Jeon, Young-Woo, Shin, Seung-Hwan, Yoon, Jae-Ho, Lee, Sung-Eun, Cho, Byung Sik, Eom, Ki-Seong, Kim, Yoo-Jin, Lee, Seok, Min, Chang-Ki, Cho, Seok-Goo, Lee, Jong Wook, and Kim, Hee-Je

Abstract

Background: Evidence that a venetoclax (VEN)-combined regimen is effective in relapsed/refractory acute myeloid leukemia (R/R AML) is emerging. However, it is unknown how VEN-combined low intensity treatment compares to intensive chemotherapy (IC) in medically fit patients with R/R AML.Methods: We compared AML patients who received IC (n= 89) to those who received a VEN in combination with hypomethylating agents or low dose cytarabine (VEN combination) (n= 54) as their first- or second-line salvage after failing anthracycline-containing intensive chemotherapy.Results: The median age was 49 years, and significantly more patients in the VEN combination group were in their second salvage and had received prior stem cell transplantation (SCT). Overall response rates including CR, CRi, and MLFS were comparable (44.0% for IC vs. 59.3% for VEN combination, p= 0.081), but VEN combination group compared to IC group tended to show lower treatment related mortality. The rate of bridging to SCT was the same (68.5%), but the percentage of SCT at blast clearance was significantly higher in the VEN-combined group (62.3% vs. 86.5%, p= 0.010). After median follow-up periods of 22.5 (IC) and 11.3 months (VEN combination), the median overall survival was 8.9 (95% CI, 5.4-12.4) and 12.4 months (95% CI, 9.5-15.2) (p= 0.724), respectively.Conclusion: VEN combination provides a comparable anti-leukemic response and survival to salvage IC, and provide a bridge to SCT with better disease control in medically-fit patients with R/R AML.

Published
2022
Full Text
View/download PDF

10. Incorporating hematopoietic stem-cell transplantation after second-line carfilzomib-lenalidomide-dexamethasone (KRd)

Author

Byun, Ja Min, Yoon, Sung-Soo, Koh, Youngil, Min, Chang-Ki, Lee, Jae Hoon, Jo, Jaemin, Park, Hyunkyung, Lee, Jiyun, Kang, Ka-Won, and Lee, Yoojin

Abstract

Background: Traditionally believed to be an integral part of multiple myeloma (MM) treatment, the role of hematopoietic stem-cell transplantation (HSCT) is being challenged. As such, we sought to evaluate the impact of HSCT in the era of novel agents.Methods: A multicenter, retrospective, longitudinal cohort study was carried out between January 2016 and December 2018. A total of 55 patients who received VTD (bortezomib-thalidomide-dexamethasone) as first-line treatment and KRd (carfilzomib-lenalidomide-dexamethasone) as second-line treatment were analyzed for outcomes.Results: The enrolled patients were divided into Group 1, defined as those who continued KRd treatment until progression (n= 41), versusGroup 2, defined as those who underwent HSCT after a certain number of cycles of KRd (n= 14). Both groups showed a generally favorable response to KRd, with overall response rate (ORR) of 87.9% and clinical benefit rate of 92.8% after a median of seven cycles in Group 1, and ORR 92.8% and clinical benefit rate 100% after median of five cycles in Group 2. However, significantly poorer progression-free survival (PFS) (p= 0.004) was observed in Group 1 (median 12 months) compared with Group 2 (median not reached). Multivariate analyses identified HSCT after KRd as potential risk factors associated with PFS. Also, in Group 1, bortezomib refractoriness was associated with significantly shorter PFS compared with those who were responsive (median 12 months versus14 months, respectively, p= 0.039).Conclusions: In conclusion, even with the advent of novel agents, HSCT still remains a valuable treatment modality with additive efficacy.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results